Concepedia

Kerry A. Whalen

KA

Statistics

Publications

5

Citations

175

H-Index

5

Active since

2005

Affiliations

Enveda Therapeutics (United States)(Current)

Tufts University

Kerry A. Whalen is an author at Enveda Therapeutics (United States) specializing in tumor-targeted ligands, polyomavirus biology, and medicine.

ORCID

Publications per year

2005–2020

5

Publications

5

Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer

Kerry A. Whalen, Brian H. White, James M. Quinn et al. · Molecular Cancer Therapeutics · 2019 · 73 citations · Full text

, , +17

Discovery of an SSTR2-Targeting Maytansinoid Conjugate (PEN-221) with Potent Activity in Vitro and in Vivo

Brian H. White, Kerry A. Whalen, Kristina Kriksciukaite et al. · Journal of Medicinal Chemistry · 2019 · 53 citations · Full text

, , +17

Genetic Analysis of the Polyomavirus DnaJ Domain

Kerry A. Whalen, Rowena de Jesus, Jennifer A. Kean et al. · Journal of Virology · 2005 · 22 citations · Full text

, , +14

Polyomavirus Middle T Antigen Induces the Transcription of Osteopontin, a Gene Important for the Migration of Transformed Cells

Kerry A. Whalen, Georg F. Weber, Thomas L. Benjamin et al. · Journal of Virology · 2008 · 16 citations · Full text

, , +14

Novel Miniaturized Drug Conjugate Leverages HSP90-driven Tumor Accumulation to Overcome PI3K Inhibitor Delivery Challenges to Solid Tumors

Samantha Perino, Benoît Moreau, Jessica Freda et al. · Molecular Cancer Therapeutics · 2020 · 11 citations · Full text

, , +15

1–5 of 5